Form 4: Regis director awarded 2,727-share grant

Regis Corp director Michael J. Mansbach received 2,727 shares at no cost, vesting by Nov. 14, 2026 or the next annual meeting, bringing direct holdings to 8,114 shares.

Summary

• Director Michael Joseph Mansbach acquired 2,727 shares of Regis Corp (RGS) common stock on 2025-11-14.
• The award was granted at $0 per share and is subject to vesting conditions.
• Post-transaction, Mansbach directly owns 8,114 shares.
• The equity award vests on the earlier of 2026-11-14 or the issuer’s next annual meeting after 2025-11-14, contingent on continued service.
• No derivative securities were reported.
• The Form 4 was signed by attorney-in-fact Amy C. Seidel on 2025-11-18.

Sentiment

Score: 5

Explanation: Routine, non-cash director equity grant with standard vesting; neutral impact on fundamentals.

Positives

• Director increased equity exposure by 2,727 shares, aligning board and shareholder interests.
• No cash consideration ($0 price) suggests the grant is standard board compensation rather than a sale or disposition.
• Clear vesting schedule provides transparency on potential future share availability.

Negatives

• Shares are unvested and contingent on continued service, so they may not fully accrue to the director if conditions aren’t met.

Risks

• Award is subject to forfeiture if continued service conditions are not met before the earlier of 2026-11-14 or the next annual meeting after 2025-11-14.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4.

Management Comments

• Equity award vests on the earlier of 2026-11-14 or the issuer’s next annual meeting after 2025-11-14, subject to continued service and the grant’s terms.

Industry Context

Annual equity grants to non-employee directors that vest at the next annual meeting are standard practice among U.S. public companies to align incentives and retain board members.

Comparison to Industry Standards

• Grant structure (time-based vesting to next AGM) aligns with common S&P SmallCap and micro-cap governance practices for non-employee director compensation.
• Use of full-value equity (restricted stock) rather than options is consistent with a broad shift across public companies toward simpler, less dilutive director compensation models.
• Size of grant (2,727 shares) appears modest relative to many peers’ annual equity retainers, though exact dollar value cannot be inferred without the share price.

Related Party Transactions

• Director compensation via equity grant: 2,727 shares of common stock to Michael J. Mansbach at $0, subject to vesting.

Stakeholder Impact

• Shareholders: Minimal dilution from a small director equity grant; improved alignment of incentives.
• Board/Management: Supports retention and alignment through time-based vesting.
• No direct impact on customers, employees, suppliers, or creditors disclosed.

Next Steps

• Monitor vesting by 2026-11-14 or at the next annual meeting after 2025-11-14, subject to continued service.
• Track any subsequent Form 4 filings for additional grants, dispositions, or changes in beneficial ownership.

Key Dates

Keywords

Regis Corp, RGS, Form 4, insider transaction, director stock grant, equity compensation, restricted stock, beneficial ownership, board compensation, vesting